Purchase this article with an account.
Chau-Minh Phan, Lyndon William Jones, Lakshman N Subbaraman, Magdalena Bajgrowicz; Release of fluconazole from daily disposable contact lenses using a novel in vitro eye model. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3085.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The burst release of a drug followed by a plateau phase is a common observation with drug delivery studies using soft contact lenses (CLs). However, this phenomenon could be attributed to the properties of the release system. The aim of this study was to evaluate and compare the release of fluconazole from a variety of daily disposable (DD) CLs using a conventional vial-based method with a novel in vitro eye model.
An eye model was created using two 3-D printed molds, which were filled with polydimethylsiloxane (PDMS) to obtain a model that mimics the eyeball and eyelid. The model was integrated with a microfluidic syringe pump, and the flow-through was collected in a 12‑well microliter plate. Four commercially available DD conventional hydrogel (CH) CLs (nelfilcon A, omafilcon A, etafilcon A, ocufilcon B) and three silicone hydrogel (SH) CLs (somofilcon A, narafilcon A, delefilcon A) were evaluated. These lenses were incubated with fluconazole for 24 h. The release of the drug was measured in (1) a vial containing 4.8 mL of PBS and (2) in the novel PDMS eye model with a 4.8 mL tear flow over 24 h. The uptake and release of the drug was monitored by absorbance at 259 nm.
Overall, CH CLs had a higher uptake and release of fluconazole than SH CLs (p<0.05). A higher drug release was observed in the vial condition compared to the eye model (p<0.001). Total drug release in the vial varied between 47.8±14.6 - 191.9±15.0 µg/lens, compared to the release in the eye model, which ranged between 45.2±3.75 - 137.5±13.8 µg/lens. In the vial system, the drug was rapidly released from the CL within the first 2 hrs, followed by a plateau phase. In contrast, drug release in the eye model was sustained, and did not reach a plateau over 24 hrs (p<0.05). Both models were in agreement as to which lenses released the highest (ocufilcon B) and lowest (nelfilcon A and narafilcon A) amount of drug.
A novel in vitro model that mimics tear flow across the ocular surface has been successfully developed, which can be used for determining drug release from CLs. Results suggest that the previously reported rapid drug release and plateau phenomenon results from using a large volume vial as the release system. Under low volume at physiological tear flow, commercial CLs can maintain a sustained drug release profile for up to 24 hrs, suggesting their potential as ocular drug delivery devices.<br />
This PDF is available to Subscribers Only